Can You Use HSA or FSA Money for Zepbound?

What Makes Zepbound HSA/FSA Eligible

Zepbound is an IRS-recognized qualified medical expense when prescribed by a clinician to treat a medical condition. The IRS does not publish a drug-specific list. Eligibility turns on whether the drug is treating a diagnosed illness rather than serving a general wellness purpose. Because Zepbound carries FDA approval for chronic weight management in adults with obesity or overweight plus at least one weight-related comorbidity, it meets the IRS "treatment of disease" standard under IRS Publication 502.

The Prescription Is Your Proof

Your HSA or FSA administrator will ask for a letter of medical necessity (LMN) or a copy of the prescription if the expense is audited. Ask your WomanRx clinician for an LMN that includes:

• Your diagnosis code (ICD-10 E66.xx for obesity, or E11.xx for type 2 diabetes if applicable)
• The prescribing clinician's NPI and signature
• The medical rationale in plain language
• The expected duration of treatment

Keep this document for at least three years. The IRS audit window for health-expense records is three years from the filing date of the return for the year you claimed the deduction.

What Qualifies You Medically

The FDA-approved indication for Zepbound requires either a BMI <30 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease) or a BMI <35 kg/m² without a comorbidity. Most women presenting to WomanRx with PCOS, perimenopausal metabolic changes, or insulin resistance will meet one of these thresholds. A clinical evaluation documents the indication, which then supports both insurance coverage and HSA/FSA reimbursement.

How to Submit an HSA or FSA Claim for Zepbound

The submission process is straightforward, though the exact steps vary by plan administrator.

Step 1: Pay at the Pharmacy

Pay out of pocket at the pharmacy or through Lilly Direct and keep the itemized receipt. The receipt must show the drug name, fill date, quantity dispensed, and amount paid. A credit-card statement alone is not sufficient.

Step 2: Gather Your Documentation

You need three documents for a clean submission:

1. Itemized pharmacy receipt (or Lilly Direct invoice)
2. Copy of the prescription or LMN from your clinician
3. Your HSA/FSA administrator's claim form (usually downloadable from their portal)

Step 3: Submit Online, by App, or by Mail

Most major HSA/FSA administrators (Optum Bank, HealthEquity, WEX, Lively, Fidelity) accept claim submissions through their mobile apps or online portals. Upload your receipt and LMN together. Processing typically takes 3 to 7 business days for online submissions and up to 15 business days for mailed paper claims.

Step 4: Use Your HSA/FSA Debit Card Directly (When Possible)

Some specialty pharmacies and compounding pharmacies that dispense tirzepatide will accept an HSA or FSA debit card at the point of sale, removing the need to file a reimbursement claim. Lilly Direct does not currently accept HSA/FSA debit cards directly as of early 2026, so reimbursement submission is required for that channel. Verify current payment options at checkout because policies change.

Common Reasons Claims Are Denied and How to Fix Them

| Denial Reason | Fix | |---|---| | Missing LMN | Upload a signed LMN with diagnosis code from your clinician | | Receipt not itemized | Request an itemized receipt from the pharmacy | | "Cosmetic / general wellness" flag | Submit a one-page appeal citing IRS Pub 502 and the FDA indication | | Benefit-year timing error | Confirm the service date falls within your FSA plan year | | Dependent not covered | Verify your FSA plan covers your dependents' prescriptions |

How Much Zepbound Actually Costs, and How to Pay Less

The list price of Zepbound is $1,059.87 per month for a single-dose pen at any dose level, which places it out of reach without a subsidy for most women. Several stacking strategies can bring that number down substantially.

The Lilly Savings Card

Eli Lilly offers a savings card for commercially insured patients who have a Zepbound prescription but face a coverage gap or high co-pay. As of early 2026, the card covers costs above your co-pay up to a maximum benefit that varies by program terms. The program has changed multiple times since Zepbound's 2023 approval, so check the current terms directly at Lilly's official savings page before assuming any specific dollar amount applies to your situation. Patients on Medicare, Medicaid, or any federal health program are not eligible for the savings card.

Lilly Direct Self-Pay Vials

In 2024, Lilly launched a direct-to-patient program offering tirzepatide vials (not pens) at significantly lower prices than the branded pen. As of early 2026, self-pay vials start at approximately $349 per month for the 2.5 mg and 5 mg doses. The vials require drawing and injecting a dose yourself, which differs from the auto-injector pen. Your WomanRx clinician can walk you through the technique. These vials are the same FDA-approved tirzepatide as the branded pen, not a compounded product.

HSA/FSA Dollars on Top of Lilly Direct

You can pay for Lilly Direct vials with HSA or FSA funds through reimbursement after the fact (since Lilly Direct does not accept HSA/FSA debit cards directly as of this writing). Paying $349 per month with pre-tax dollars at a 22% federal tax bracket saves roughly $77 per month compared to paying with after-tax income. Over 12 months, that is close to $924 in tax savings on the drug cost alone.

Insurance Coverage Is Shifting

Obesity medicine coverage expanded after the American Heart Association, the American College of Cardiology, and a broad coalition published the 2022 joint obesity guideline, and some commercial plans now cover GLP-1 receptor agonists and dual agonists approved for obesity. However, many employer-sponsored plans still exclude weight-loss drugs by plan design. The only reliable way to know your benefit is to call the member services number on your insurance card and ask specifically whether Zepbound (NDC prefix 00002-1513 for the pen series) is covered under your formulary. If it is covered but requires prior authorization, your WomanRx clinician can submit clinical notes documenting your qualifying diagnosis.

Sex-Specific Physiology: Why Zepbound Works Differently in Women

Women's metabolic physiology differs from men's in ways that affect both how tirzepatide works and what side effects you are likely to experience. This is a framework we use at WomanRx to help clinicians personalize dosing conversations, and it is not yet reflected in any single published guideline.

Hormonal Status and GLP-1 Receptor Sensitivity

Estrogen appears to upregulate GLP-1 receptor expression in the hypothalamus and pancreas. Preclinical data published in Diabetes show that estrogen-deficient rodents have blunted GLP-1-induced satiety responses that are restored with estrogen replacement. This may explain the clinical observation that perimenopausal and postmenopausal women sometimes require longer titration to find an effective dose of GLP-1 class drugs, though direct human trial data in this population remain thin. WomanRx clinicians account for this when setting titration schedules for women over 45.

Body Composition and Fat Distribution

Women carry a higher percentage of body fat than men at the same BMI. The SURMOUNT-1 trial, which enrolled 2,539 participants and demonstrated up to 22.5% mean body weight reduction at 72 weeks on tirzepatide 15 mg, reported that women achieved weight loss similar to or slightly greater than men in the overall analysis. Sex-stratified responder data from SURMOUNT-1 were not fully published at the time of this article's last review, which represents a genuine evidence gap. What is known is that women tend to lose proportionally more subcutaneous fat and men more visceral fat with GLP-1 class drugs, which has downstream implications for cardiovascular risk reduction.

The Menstrual Cycle and Nausea Timing

Nausea is the most common side effect of tirzepatide, reported in approximately 31% of participants on the 15 mg dose in SURMOUNT-1. Women in the luteal phase of their cycle (days 14 to 28) already experience elevated progesterone-driven gastric slowing and nausea susceptibility. Stacking an injection on top of the luteal-phase nausea window can amplify side effects. Some WomanRx patients find that scheduling their weekly injection for the follicular phase (days 1 to 13) reduces nausea intensity, though no randomized trial has tested this. It is a practical strategy worth discussing with your clinician.

PCOS and Insulin Resistance

PCOS affects an estimated 8% to 13% of women of reproductive age globally, and insulin resistance is a central feature in most phenotypes. Tirzepatide targets both GLP-1 and GIP receptors simultaneously, making it pharmacologically well-suited to the insulin-resistant woman. Small observational studies suggest improvements in menstrual regularity and androgen levels with GLP-1 class drugs in women with PCOS, though no large randomized controlled trial has yet been completed specifically in a PCOS population for tirzepatide. ACOG acknowledges GLP-1 receptor agonists as a consideration in PCOS management in its 2023 clinical guidance, though formal labeling does not yet include this indication.

Perimenopause and Postmenopause

The menopause transition is associated with a shift toward central adiposity, worsening insulin sensitivity, and increased cardiovascular risk even in women who do not gain weight. The Menopause Society's 2023 position statement on menopause and metabolic health acknowledges that weight gain in perimenopause is driven by hormonal change rather than lifestyle alone, and that anti-obesity medications may be appropriate adjuncts in this population. For postmenopausal women, bone density monitoring is relevant because rapid weight loss from any cause can accelerate bone loss. Your WomanRx clinician should discuss a DEXA scan if you are losing more than 1 to 2 pounds per week for an extended period.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting Zepbound

Zepbound is contraindicated in pregnancy. This is not a relative caution. It is an absolute contraindication.

Pregnancy Safety Data

Animal studies conducted by Lilly showed dose-dependent fetal harm at exposures below the human therapeutic dose, including reduced fetal weight and skeletal malformations. The FDA prescribing information for Zepbound states that the drug should be discontinued at least two months before a planned pregnancy based on the drug's half-life and washout period. There are no adequate and well-controlled human studies in pregnant women. The drug has not been assigned a formal letter category under the old FDA system (which was phased out), but under the current labeling framework, the pregnancy risk summary is explicit: avoid use.

Contraception Requirement

Women of reproductive age who are not actively trying to conceive must use reliable contraception while on Zepbound. Tirzepatide slows gastric emptying, which can reduce the absorption and peak plasma concentration of oral contraceptives. FDA prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after each dose escalation. After dose is stable, the interaction is less pronounced but not zero. Your WomanRx clinician will review your current contraception method before prescribing.

Fertility Considerations

Rapid weight loss and improved insulin sensitivity from tirzepatide can restore ovulatory cycles in women with PCOS or obesity-related anovulation who were not previously ovulating. This means pregnancy risk may increase even in women who previously relied on irregular cycles as informal contraception. If you are not trying to conceive, this matters. If you are trying to conceive, Zepbound must be stopped and fully washed out before attempting pregnancy.

Lactation

No human lactation data for tirzepatide exist as of early 2026. Animal data on transfer into breast milk are limited. Because the drug is a large peptide that would likely be degraded in the infant's gastrointestinal tract, systemic absorption by the infant is theoretically low, but theoretical reassurance is not the same as safety data. LactMed, the NIH's drug and lactation database, classifies tirzepatide as having insufficient data to assess safety in breastfeeding. The standard clinical recommendation is to avoid tirzepatide while breastfeeding. Discuss the timing of postpartum weight management with your clinician, including when it may be appropriate to transition to pharmacotherapy after weaning.

Who This Is Right For, and Who Should Wait

Women Who Are Good Candidates

• BMI <30 kg/m² with a documented comorbidity such as hypertension, pre-diabetes, sleep apnea, or dyslipidemia
• Women with PCOS and insulin resistance who have not met weight or metabolic goals with lifestyle change alone
• Perimenopausal or postmenopausal women with central adiposity and rising cardiovascular risk markers
• Women who have tried other anti-obesity medications without adequate response
• Women with commercial insurance, an HSA, or FSA who can offset the cost

Women Who Should Not Use Zepbound

• Anyone currently pregnant or planning pregnancy within two months
• Anyone breastfeeding
• Women with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), per the FDA black-box warning
• Women with a history of pancreatitis (relative contraindication requiring careful discussion)
• Women on Medicare or Medicaid who cannot access the Lilly savings card and for whom cost is the primary barrier without another coverage pathway

Women in the Middle: Trying to Conceive

If you are actively trying to conceive, Zepbound is not appropriate. Weight loss before conception does improve fertility outcomes in women with obesity-related anovulation, and your clinician may recommend a structured, supervised plan to achieve a target weight before a planned conception cycle. The two-month washout before attempting pregnancy should be built into your preconception timeline.

How to Use HSA and FSA Together When You Have Both

Some women have both an HSA and a limited-purpose FSA (LPFSA), or a dependent-care FSA alongside a general-purpose FSA. The rules for combining accounts are strict:

• You cannot contribute to a general-purpose FSA and a general HSA in the same year. Doing so makes your HSA contributions non-deductible and potentially subject to a 6% excise tax.
• A limited-purpose FSA (restricted to dental and vision) CAN coexist with an HSA and does not affect HSA eligibility.
• If you have an HSA-compatible high-deductible health plan (HDHP) and a general-purpose FSA through your spouse's employer, that FSA also disqualifies you from HSA contributions for the year, per IRS Notice 2004-2.

The practical takeaway: use FSA dollars first when possible, because FSA funds have a "use it or lose it" feature (with a limited rollover of up to $640 in 2024 plan years). HSA dollars roll over indefinitely and grow tax-free, so preserving them for future years is often smarter.

The 2026 Field: What Has Changed and What May Change Again

Zepbound's access field has shifted multiple times since its November 2023 FDA approval. Compound pharmacies were permitted to produce tirzepatide during the FDA drug shortage period. The FDA officially removed tirzepatide from the drug shortage list in late 2024, which means FDA-registered compounders can no longer legally produce copies of Zepbound solely on the basis of the shortage designation. As of early 2026, the legal status of compounded tirzepatide remains a contested area with ongoing FDA guidance and litigation. WomanRx does not prescribe compounded tirzepatide through non-FDA-registered facilities.

Employer benefit trends are moving toward limited GLP-1 coverage. A 2024 KFF Employer Health Benefits Survey found that 18% of large employers (200 or more employees) covered GLP-1 drugs for obesity, up from under 10% in 2022. That share is expected to continue growing as cardiovascular outcomes data from SURMOUNT-MMO mature. If your plan does not cover Zepbound today, it may next open-enrollment period. File an appeal now if you have been denied, because a successful appeal establishes a coverage precedent in your plan's records.